











## **Prior Authorization Request Administrative Information**

Member Information				
Last name	First name		МІ	
Member ID	Date of birth			
	X" or Intersex			
Current gender  Female  Male  Transge	ender male 🔲 Tra	nsgender female  Othe	-	
Place of residence Home Nursing facility	Other			
Race/ethnicity Preferred spoken la	anguage	Preferred written lang	uage	
MassHealth does not exclude people or treat them differently because of race, color, national origin, age, disability, religion, creed, sexual orientation, or sex (including gender identity and gender stereotyping).				
Plan Contact Information				
Please indicate the member's MassHealth Plan according to the Plan's contact information belo		his completed and signed	form	
MassHealth Fee-For-Service (FFS) Plan, Primary Care Clinician (PCC) Plan, Primary Care Accountable Care Organization (PCACO) Plan, Children's Medical Security Plan, and Health Safety Net Plan				
☐ MassHealth Drug Utilization Review Prog	gram			
Pharmacy: Fax: (877) 208-7428 - Tel: (800	) 745-7318			
MassHealth Managed Care Organization (MCO) and Accountable Care Partnership Plans (ACPP)				
☐ Fallon Health				
Online Prior Authorization: go.covermymeds.com/OptumRx				
Online Prior Authorization: providerportal.s	urescripts.net/Provi	derPortal/optum		
Pharmacy: Fax: (844) 403-1029 - Tel: (844) 720-0033				
☐ Health New England				
Online Prior Authorization: go.covermymeds.com/OptumRx				
Pharmacy: Fax: (800) 550-9246 - Tel: (800) 918-7545				
Online Prior Authorization (Non-Specialty Drugs): go.covermymeds.com/OptumRx				
Online Prior Authorization (Specialty/Medical Drugs): provider.massgeneralbrighamhealthplan.org				
Pharmacy: Fax: (844) 403-1029 - Tel: (800) 711-4555				
☐ Tufts Health Plan				
Online Prior Authorization: point32health.promptpa.com				
Pharmacy: Fax: (617) 673-0939 - Tel: (888) 257-1985				
□ WellSense Health Plan				
Online Prior Authorization: wellsense.org/p	roviders/ma/pharma	acy/prior-authorizations		
Pharmacy: Fax: (833) 951-1680 - Tel: (877) 417-1822				

## **Gout Agents Prior Authorization Request**

MassHealth reviews requests for prior authorization (PA) on the basis of medical necessity only. If MassHealth approves the request, payment is still subject to all general conditions of MassHealth, including current member eligibility, other insurance, and program restrictions. MassHealth will notify the requesting provider and member of its decision. Keep a copy of this form for your records. If faxing this form, please use black ink.

Additional information about these agents, including PA requirements and preferred products, can be found within the MassHealth Drug List at www.mass.gov/druglist.

Medication information					
Medication requested  ☐ allopurinol 200 mg tablet ☐ colchicine capsule ☐ febuxostat	☐ Gloperba (colchicine☐ Krystexxa (peglotica	·			
MB This drug is available through the health care professional who administers the drug or in an outpatient or inpatient hospital setting. MassHealth does not pay for this drug to be dispensed through the retail pharmacy. If listed, prior authorization does not apply through the hospital outpatient and inpatient settings. Please refer to 130 CMR 433.408 for prior authorization requirements for other health care professionals. Notwithstanding the above, this drug may be an exception to the unified pharmacy policy; please refer to respective MassHealth Accountable Care Partnership Plans (ACPPs) and Managed Care Organizations (MCOs) for prior authorization status and criteria, if applicable.					
Dose and frequency of medication requested					
Indication (Check all that apply or include ICD-10 code, if	applicable.)				
☐ Prophylaxis of gout					
☐ Treatment of gout	Other	ding medical necessity.)			
Please provide any serum urate level results and date	`	uing medical necessity.)			
1. Lab value Date obtained	3. Lab value	Date obtained			
2. Lab value Date obtained	4. Lab value	Date obtained			
Please provide creatinine clearance level result and date obtained.  Date obtained  Please indicate billing preference.  Pharmacy Prescriber in-office Hospital outpatient  If applicable, please also complete section for professionally administered medications at end of form.					
Section I. Please complete for prophylactic use of colchicine capsule or Gloperba (colchicine solution) for gout with urate lowering therapy.*					
<ol> <li>Will the member be taking the requested medication or probenecid?</li> </ol>	•	·			
Yes. Please document drug name with dose and fr					
Drug Dose and Frequence	-	Dates/Duration			
No. Please describe clinical rationale why concurre	ent therapy is not appropria	te for this member.			

PA-32 (Rev. 04/24) over

2.	What is the expected duration of therapy? <b>Please note:</b> requests for > six months will require additional clinical rationale for need of further treatment.
3.	Does the member have tophaceous gout?   Yes   No
	For Gloperba, is there a medical necessity for the use of a solution formulation?
	☐ Yes. Please explain. ☐ No
5.	For colchicine capsule, please provide clinical rationale for the use instead of colchicine tablet.
Sec	tion II. Please complete for prophylactic use of colchicine capsule or Gloperba (colchicine solution) for gout without urate lowering therapy.*
1.	Has the member tried allopurinol and experienced an adverse reaction or inadequate response?  [ Yes. Please document dose and frequency, dates of use, and outcome.
	Dose and Frequency  Dates/Duration  Outcome  No. Please document if there is a contraindication to allopurinol therapy.
2.	Has the member tried febuxostat and experienced an adverse reaction or inadequate response?  Yes. Please document dose and frequency, dates of use, and outcome.  Dose and Frequency  Dates/Duration  Outcome
	☐ No. Please document if there is a contraindication to febuxostat therapy.
3.	For Gloperba, is there a medical necessity for the use of a solution formulation?  Yes. Please explain.
4.	☐ No For colchicine capsule, please provide clinical rationale for the use instead of colchicine tablet.
_	
	tion III. Please complete for treatment of gout with Krystexxa (pegloticase).*
1.	Has the member tried allopurinol and experienced an adverse reaction or inadequate response?  Yes. Please document dose and frequency, dates of use, and outcome.
	Dose and Frequency Dates/Duration Outcome  No. Please document if there is a contraindication to allopurinol therapy.
2	Has the member tried febuxostat and experienced an adverse reaction or inadequate response?
۷.	Yes. Please document dose and frequency, dates of use, and outcome.
	Dose and Frequency  Dates/Duration  Outcome  No. Please document if there is a contraindication to febuxostat therapy.

3.	adverse reaction or inadequate response?					
	Drug Drug	es with dose and frequency, dates of use, and outcome.  Dose and Frequency				
	Dates/Duration	Outcome				
	Drug	Dose and Frequency				
	Dates/Duration	Outcome				
		a contraindication to uricosuric agent therapy.				
	Has the member tried allopurinol and Yes. Please document dose and Dose and Frequency	eatment of gout with febuxostat.* d experienced an adverse reaction or inadequate response? frequency, dates of use, and outcome.  Dates/Duration Outcome a contraindication to allopurinol therapy.				
2.	For requests exceeding quantity limi	its, please provide medical necessity for dosing.				
1.	Please attach medical records docur 100 mg tablets.	eatment of gout with allopurinol 200 mg tablet.* menting an inadequate response or adverse reaction to allopurinol two- ity for use of allopurinol 200 mg tablet instead of two 100 mg tablets.				
*Ple	ease attach a letter documenting addi	itional trials as necessary.				
	Is the alternative drug required under adverse reaction in, or physical or m	rovide documentation for exceptions to Step Therapy.  er the step therapy protocol contraindicated, or will likely cause an inental harm to the member?   Yes  No traindication, adverse reaction, or harm.				
2.	known clinical characteristics of the Yes No	er the step therapy protocol expected to be ineffective based on the member and the known characteristics of the alternative drug regimen?				
	ii yes, briefly describe details of know	wn clinical characteristics of member and alternative drug regimen.				

3.	Has the member previously tried the alternative drug required under the step therapy protocol, or another alternative drug in the same pharmacologic class or with the same mechanism of action, and such alternative			
	drug was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?			
	☐ Yes ☐ No			
	If yes, please provide details for the previous trial.			
	Drug name Dates/duration of use			
Did the member experience any of the following?   Adverse reaction   Inadequate response				
	Briefly describe details of adverse reaction or inadequate response.			
4.	4. Is the member stable on the requested prescription drug prescribed by the health care provider, and switchin drugs will likely cause an adverse reaction in or physical or mental harm to the member?			
	☐ Yes. Please provide details.			
	□ No			

Please continue to next page and complete Prescriber and Provider Information section.

## **Prior Authorization Request Prescriber and Provider Information**

Prescriber Information		
Last name*	First name*	MI
NPI*	Individual MH Provide	er ID
DEA No.	Office Contact Name	
Address	City	State Zip
Email address		
Telephone No.*	Fax No.*	
* Required		
Please also complete for professionally	administered medication	ns, if applicable.
Start date	End date	
Servicing prescriber/facility name		☐ Same as prescribing provider
Servicing provider/facility address		
Servicing provider NPI/tax ID No.		
Name of billing provider		
Billing provider NPI No.		
Is this a request for recertification?  Yes	] No	
CPT code No. of visits	J code	No. of units
Prescribing provider's attestation, signal certify under the pains and penalties of perjoinformation section of this form. Any attached I certify that the medical necessity information complete, to the best of my knowledge. I under prosecution for any falsification, omission, or	ury that I am the prescribing I statement on my letterhead (per 130 CMR 450.204) on erstand that I may be subject concealment of any material	has been reviewed and signed by me. this form is true, accurate, and to civil penalties or criminal I fact contained herein.
Prescribing provider's signature		_
Printed name of prescribing provider  (The form can either be signed by hand and		

(The form can either be signed by hand and then scanned, or it can be signed electronically using DocuSign or Adobe Sign. For electronic signatures, the signer can upload a picture of their wet signature. The typed text of a signature is not an acceptable form of an electronic signature.)